Roxatidine acetate

Roxatidine acetate

Roxatidine acetate
Systematic (IUPAC) name
2-oxo-2-(3-[3-(piperidin-1-ylmethyl)phenoxy]propylamino)ethyl acetate
Clinical data
Routes of
Pharmacokinetic data
Bioavailability 80–90%
Protein binding 5–7%
Metabolism Hepatic deacetylation
Minor involvement of CYP2D6 and CYP2A6
Biological half-life 5–7 hours
Excretion Renal
CAS Registry Number  N
ATC code A02
PubChem CID:
DrugBank  Y
ChemSpider  Y
Chemical data
Formula C19H28N2O4
Molecular mass 348.437 g/mol

Roxatidine acetate is a specific and competitive histamine H2 receptor antagonist drug that is used to treat gastric ulcers, Zollinger–Ellison syndrome, erosive esophagitis, gastro-oesophageal reflux disease, and gastritis.[1][2]

Pharmacodynamic studies showed that 150 mg of roxatidine acetate were optimal in suppressing gastric acid secretion, and that a single bedtime dose of 150 mg was more effective than a dose of 75 mg twice daily in terms of inhibiting nocturnal acid secretion.[1]

It is available in countries including China, Japan, Korea, Germany, Italy, the Netherlands, Greece and South Africa.[2]


  1. ^ a b Murdoch D, McTavish D (1991). "Roxatidine acetate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders". Drugs 42 (2): 240–260.  
  2. ^ a b BioSpectrum Bureau 1 November 2012 Sinhuan's generic heart drug gets production approval